Abnormalities in response to vasopressin infusion in chronic fatigue syndrome

Psychoneuroendocrinology

Volumn 26, Issue 2, 2001, Pages 175-188

  Altemus, Margaret ^a   Dale, Janet K ^b   Michelson, David ^d   Demitrack, Mark A ^d   Gold, Philip W ^c   Straus, Stephen E ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

ACTH; Chronic fatigue syndrome; Cortisol; CRH; HPA axis; Vasopressin

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; HYDROCORTISONE; VASOPRESSIN;

ADULT; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INFUSION; DRUG RESPONSE; FEMALE; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NEUROENDOCRINE DISEASE; PRIORITY JOURNAL; VOLUNTEER;

EID: 0035219612     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(00)00044-5     Document Type: Article

References (74)

1. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder
2. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age
3. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome
4. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome
5. An inventory for measuring depression
6. Spectrum of pituitary alterations with mild and severe thyroid impairment
7. The relationship between neurally mediated hypotension and the chronic fatigue syndrome
8. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty
9. Corticotropin releasing factor: actions on the sympathetic nervous system and metabolism
10. Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis
11. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome
12. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial
13. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome
14. Arginine vasopressin potentiates adrenocorticotropin release induced by corticotropin releasing factor
15. Neuroendocrine aspects of chronic fatigue syndrome: Implications for diagnosis and research
16. Evidence for impaired activation of the hypothalamic-pituitary adrenal axis in patients with chronic fatigue syndrome
17. Serotonin-mediated activation of the hypothalamic-pituitary axis in chronic fatigue syndrome
18. Muscle histopathology and physiology in chronic fatigue syndrome
19. The chronic fatigue syndrome
20. Exercise performance and fatiguability in patients with chronic fatigue syndrome
21. Chronic fatigue: a prospective clinical and virologic study
22. Development of a rating scale for primary depressive illness
23. Paradoxical responses of hypothalamic corticotropin releasing factor (CRF) messenger RNA (m-RNA) and CRF-41 peptide and adenohypophysial proopiomelanocortin mRNA during chronic inflammatory stress
24. Abuse-related post-traumatic stress disorder and alterations of the hypothalamic-pituitary adrenal axis in women with chronic pelvic pain
25. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders
26. Syndrome following abrupt cessation of prolonged cortisone therapy
27. The psychiatric status of patients with chronic fatigue
28. Chronic fatigue syndrome: a working case definition
29. Abnormal pituitary-adrenal responses to oCRH in patients with seasonal affective disorder: clinical and pathophysiological implications
30. Effect of altered thyroid hormone levels on hypothalamic-pituitary-adrenal disorders
31. The clinical evaluation of chemotherapeutic agents in cancer
32. Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis
33. Assessment of adrenocortical function in the course of viral hepatitis
34. Sickness behaviour as a new target for drug development
35. Central basis of muscle fatigue in chronic fatigue syndrome
36. Psychiatric diagnoses in patients with the chronic fatigue syndrome
37. Depression and somatization in the chronic fatigue syndrome
38. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome
39. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise
40. The mental health of patients with chief complaint of chronic fatigue syndrome: a prospective evaluation and follow up
41. Immune responses associated with chronic fatigue syndrome: a case-control study
42. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis
43. Low-dose hydrocortisone for treatment of chronic fatigue syndrome
44. Adrenocortical function in acquired immunodeficiency syndrome
45. Involvement of hypothalamic corticotropin-releasing factor neurons in behavioral responses to noverlty in rats
46. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function
47. CRF in the paraventricular nucleus of the hypothalamus induces dose-released behavioral profile in rats
48. Physiological functions of glucocorticoids in stress and their relations to pharmacological actions
49. Adrenocortical activity and some clinical findings in acute and chronic fatigue
50. Aerobic work capacity in patients with chronic fatigue syndrome
51. Elevated glucocorticoid receptor concentrations before and after glucocorticoid treatment in atopic dermatitis
52. Human quadriceps strength and fatiguability in patients with post-viral fatigue
53. Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhytm of ACTH
54. Response to exercise after bed rest and training: a longitudinal study of adaptive changes in oxygen transport and body composition
55. Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome or depression
56. Evidence for differential regulation of corticotropin-releasing factor and vaopressin immunoreactivities in parvocellular neurosecretory and autonomic-related projections of the paraventricular nucleus
57. Urinary free cortisol levels in chronic fatigue syndrome, major depression and in healthy volunteers
58. The low dose ACTH test in chronic fatigue syndrome and in health
59. Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome
60. Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome
61. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers
62. Increased prolactin response to buspirone in chronic fatigue syndrome
63. Medical consequences of persisitent viral infection
64. A comparison of salivary cortisol in chronic fatigue sydrome, community depression and healthy controls
65. Immunological function in chronic fatigue syndrome
66. Corticotropin-releasing factor produces behavioural activation in rats
67. Salivary cortisol profiles in chronic fatigue syndrome
68. Psychoneuroendocrinology of post-traumatic stress disorder
69. Enhanced suppression of cortisol following a low dose of dexamethasone in combat veterans with posttraumatic stress disorder
70. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome